Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
BeyondSpring Inc. is a clinical-stage biopharmaceutical company focused on the development of innovative cancer therapies. The company operates within the oncology and biopharmaceutical research and development industries, with its business centered on advancing novel drug candidates through clinical development rather than commercial sales. BeyondSpring’s activities are primarily research-driven, and it has not reported product revenue from approved therapies as of the latest publicly available filings.
The company’s core focus is on its lead drug candidate Plinabulin, a small-molecule immune-modulating agent being developed primarily for the treatment of cancer-related indications. BeyondSpring targets patients undergoing chemotherapy, with an emphasis on improving clinical outcomes and addressing unmet medical needs. The company was founded in 2010 and later completed a public listing on Nasdaq, evolving from an early-stage research organization into a publicly traded clinical-stage biotechnology company with global clinical trial activities.
Business Operations
BeyondSpring’s operations are organized around a single operating segment focused on oncology drug development, with substantially all resources dedicated to research, clinical trials, regulatory activities, and corporate administration. The company does not operate commercial manufacturing or sales infrastructure and instead relies on third-party contract research organizations and manufacturers to support clinical development and trial execution.
The company’s primary asset, Plinabulin, is being evaluated across multiple oncology-related indications, including chemotherapy-induced neutropenia and certain cancer treatment combinations. BeyondSpring conducts operations through its U.S.-based parent company and affiliated entities, including BeyondSpring Pharmaceuticals, Inc., which supports development activities. International operations, particularly in China, are integral to its clinical trial strategy, with certain studies conducted through local partners and subsidiaries. Revenue generation to date has primarily consisted of limited collaboration-related income and interest, with the company remaining dependent on external financing.
Strategic Position & Investments
BeyondSpring’s strategy centers on advancing Plinabulin through late-stage clinical development and pursuing regulatory approvals in major pharmaceutical markets. The company positions itself as a developer of differentiated oncology therapies with novel mechanisms of action, aiming to complement existing cancer treatments rather than compete directly with established chemotherapy agents.
Investment activity has been focused on internal research and development rather than acquisitions, and no material acquisitions of other operating companies have been disclosed in public filings. BeyondSpring has explored strategic collaborations to support clinical development and potential commercialization, particularly in Asia, though details of long-term commercial partnerships remain limited. The company’s emerging technology focus remains concentrated on immune-modulating approaches within oncology. Data inconclusive based on available public sources regarding any material equity investments or diversified portfolio holdings.
Geographic Footprint
BeyondSpring is headquartered in the United States, with its principal executive offices located in New York. The company maintains an international presence through clinical development activities and affiliated entities, most notably in China, where oncology clinical trials have been conducted and regulatory engagement has been pursued.
Operational influence spans North America and Asia, with clinical trial sites and development partners supporting its research programs. BeyondSpring does not report commercial operations in Europe, Latin America, or Africa, though patients in those regions may participate in multinational studies. Its geographic footprint is therefore best characterized as research-focused rather than commercially expansive.
Leadership & Governance
BeyondSpring was co-founded by Lan Huang, who has played a central role in shaping the company’s scientific and strategic direction. The leadership team emphasizes disciplined clinical development, regulatory alignment, and long-term value creation through innovation in oncology therapeutics.
Key executives and leaders include:
- Ramon Vaca – President and Chief Executive Officer
- Lan Huang – Co-founder and Chairwoman of the Board
Publicly available disclosures confirm these leadership roles; however, information regarding additional senior executive appointments and governance committee composition is limited or varies across sources. Data inconclusive based on available public sources for a comprehensive list of other current executive officers beyond those named above.